CAS 188627-80-7
:Eptifibatide
- [3-carbamoyl-11-{4-[(diaminomethylidene)amino]butyl}-20-(1H-indol-3-ylmethyl)-1,9,12,15,18,21-hexaoxodocosahydro-7H-pyrrolo[2,1-g][1,2,5,8,11,14,17,20]dithiahexaazacyclotricosin-17-yl]acetic acid
- [(1S,4R,12S,18S,21S)-12-(4-carbamimidamidobutyl)-4-carbamoyl-21-(1H-indol-3-ylmethyl)-2,10,13,16,19,22-hexaoxo-6,7-dithia-3,11,14,17,20,26-hexaazabicyclo[21.2.1]hexacos-18-yl]acetic acid
- Map-Lys-Gly-Asp-Trp-Pro-Cys-Nh2
- Integrelin
- N6-(Aminoiminomethyl)-N2-(3-mercapto-1-oxopropyl-L-lysylglycyl-L-a-aspartyl-L-tryptophyl-L-prolyl-L-cysteinamide
- [(3R,11S,17S,20S,25aS)-11-(4-carbamimidamidobutyl)-3-carbamoyl-20-(1H-indol-3-ylmethyl)-1,9,12,15,18,21-hexaoxodocosahydro-7H-pyrrolo[2,1-g][1,2,5,8,11,14,17,20]dithiahexaazacyclotricosin-17-yl]acetic acid
- Eptifibatide Acetate
- Tri par prix ascendant
- Tri par prix descendant
- Puretés inférieures
- Puretés supérieures
- Livraison estimée la plus rapide
Eptifibatide
CAS :Eptifibatide, a RGD mimetic, is a glycoprotein (GP) IIb/IIIa receptor antagonist. Clinically, the peptide is used as an antiplatelet drug in combination with heparin and aspirin in the management of unstable angina and in patients undergoing coronary angioplasty and stenting procedures. CAS Number (eptifibatide acetate): 148031-34-9.Formule :C35H49N11O9S2Degré de pureté :≥99%Couleur et forme :White LyophilisateMasse moléculaire :831.97Eptifibatide
CAS :Nucleic acids and their salts, whether or not chemically defined; other heterocyclic compounds, nesoiFormule :C35H49N11O9S2Couleur et forme :White PowderMasse moléculaire :831.31561Human Eptifibatide
CAS :Human EptifibatideFormule :C35H49N11O9S2Couleur et forme :White Solid-PowderMasse moléculaire :831.96186Eptifibatide
CAS :Formule :C35H49N11O9S2Degré de pureté :96%Couleur et forme :SolidMasse moléculaire :831.9619Eptifibatide Acetate
CAS :Formule :C35H49N11O9S2Degré de pureté :95%~99%Couleur et forme :White to Off-white PowderMasse moléculaire :831.962Eptifibatide
CAS :Produit contrôléApplications An arginine-glycine-aspartate-mimetic, reversibly binds to platelets to reduce the risk of cardiac ischemic events.
References Pathak, A., et al.: Cardiovas. Diabetol., 7 (2008), Hantgan, R., et al.: Biochem., 48, 8355 (2009), Giugliano, R., et al.: New Eng. J. Med., 360, 2176 (2009),Formule :C35H49N11O9S2Couleur et forme :NeatMasse moléculaire :831.96Eptifibatide acetate
CAS :Produit contrôléInhibits platelet glycoprotein IIb/IIIa receptorsFormule :C35H49N11O9S2·xC2H4O2Degré de pureté :Min. 95%Couleur et forme :PowderMasse moléculaire :831.96 g/molEptifibatide
CAS :Eptifibatide is a drug that is used in the treatment of congestive heart failure, acute coronary syndrome and peripheral artery disease. It is a glycoprotein IIb/IIIa inhibitor that binds to integrin receptors on platelets and prevents them from binding to fibrinogen. This prevents blood clotting and reduces the risk of stroke or heart attack. Eptifibatide has been shown to be effective for the treatment of bowel disease, infectious diseases, and experimental models of myocardial infarcts. The drug has significant cytotoxicity, which may be due to its ability to inhibit cell proliferation by blocking protein synthesis at the ribosome level.
Eptifibatide has been shown to have a disulfide bond between two cysteine residues located in its amino-terminal region. This bond stabilizes the molecule in solution and ensures that it remains active until it reaches its target site.Formule :C35H49N11O9S2Degré de pureté :Min. 95%Masse moléculaire :831.98 g/molEptifibatide
CAS :2-((3R,11S,17S,20S,25aS)-20-((1H-Indol-3-yl)methyl)-3-carbamoyl-11-(4-guanidinobutyl)-1,9,12,15,18,21-hexaoxodocosahydro-1H-pyrrolo[2,1-g][1,2,5,8,11,14,17,20]dithiahexaazacyclotricosin-17-yl)acetic acidFormule :C35H49N11O9S2Degré de pureté :96%Masse moléculaire :831.96











